FEATURED ARTICLES

• Ways To Enhance Access To Cell Therapies

  Cell therapies are revolutionizing cancer care, but their complex manufacturing and high costs bar access for many patients. Automation is emerging as an efficacious solution to reach patients in need.

• Expansion Of Cord Blood-Derived CD34+ Cells In A Hollow-Fiber Bioreactor With 10% Standard Cytokine Concentration

  CD34+ cells isolated from cord blood were expanded in a hollow-fiber bioreactor using a novel cytokine cocktail at one-tenth the standard concentration using a MSC-free coating strategy.

• Navigating The Challenges Of Bringing Cell And Gene Therapies To Market

  Cell and gene therapies are witnessing rapid advancements, but significant challenges remain for their commercialization due to regulatory hurdles, manufacturing barriers, high costs, and safety concerns.

• T-Cell Manufacturing: When Is The Right Time To Automate?

  Automation enhances efficiency and minimizes contamination risks and labor costs. Despite the initial investment in automation equipment, the long-term savings can be significant.

• How Cell And Gene Therapies Are Evolving

  Advances in manufacturing technologies and equipment are improving the efficiency and reproducibility of cell and gene therapies and helping overcome the current supply and demand imbalance.

• Harnessing The Power Of Cell And Gene Therapy In Oncology

  Advances in oncology, specifically in CAR T-cell therapies and TILs, are leading the way in cell and gene therapy. However, costs and complex regulations present challenges.

• Quality Versus Quantity In T-Cell Production

  Technological advances have made it possible to produce high-quality T cells at scale, providing a boon for T-cell manufacturing.

• iPSC Expansion In A Cell Expansion System's Small Bioreactor

  Explore how using a flexible, automated system can help expand induced pluripotent stem cells (iPSCs) faster than traditional culture methods.

• Cell Expansion System Supports Proliferation Of Regulatory T-Cells

  This study showcases a cell expansion system that is providing T-cells with an ideal environment for growth, efficient in expanding many cells quickly, and enhancing regulatory T-cell characteristics.

• HEK293T Cell Expansion Protocol Using A Hollow-Fiber Bioreactor System

  Explore the use of a hollow-fiber bioreactor (HFB) system for the automated expansion of HEK293T cells and a protocol used to help users of the system.

• Study Of Small Bioreactor Expansion Kinetics During Expansion Protocol

  Mesenchymal stem cells have been used to show equivalent expansion kinetics during a 7-day expansion protocol on both the small and standard bioreactors revealing efficiency differences.

• Quintessential Role Of Apheresis In Gene-Modified T-Cell Therapy

  Learn more about process standardization and comprehensive quality management programs as it relates to leukapheresis and cell therapy manufacturers.

• Choose The Right Bioreactor Size For Your Cell Expansion

  Compare expansion parameters when adherent cells are cultured on the small and standard bioreactors using a hollow-fiber bioreactor platform.

• Optimized Fill And Finish To Limit DMSO's Negative Impact On T Cells

  In order to improve the existing cryopreservation paradigm, operators must consider fill/finish and cryopreservation techniques that streamline processing steps and minimize cells’ exposure to DMSO.

• Matters of Scale: Centralized vs. Decentralized Manufacturing Of Advanced Therapies

  Reducing human intervention and manual processes in advanced therapy manufacturing is critical to improving a manufacturing paradigm, safeguarding quality, simplifying processes, and improving efficacy.

• Elevate Your T-Cell Manufacturing Process

  Today automation and next-generation bioreactors are two prime areas of innovation for enhancing cell manufacturing. Here we delve into some ways these innovations could improve T-cell based therapy production.

• The Monoculture Of Cord-Blood-Derived CD34+ Cells

  Explore an 8-day expansion of a 2 × 10 positively selected CD34⁺ cell inoculum from 3 donor lineages, and the results proving the automated monoculture protocol can support that expansion with minimal lymphocyte residual.

• Incorporating Automation Into Your Fill And Finish Procedure

  Incorporate automation into fill and finish procedures and learn more about the impact of automation on production costs and product quality.

• Cell Therapy's Live Analytical Challenges

  Learn about analytical science tools that can be employed to take cell and gene therapy to the next level.

• Achieve Efficiency And Quality In Cell Therapy Manufacturing

  Enabling automation, reducing manual steps, and implementing standard procedures is key to success in cell therapy manufacturing.